Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 31:16:17588359241242959.
doi: 10.1177/17588359241242959. eCollection 2024.

PARP inhibitors in prostate cancers, is it time for combinations?

Diego Teyssonneau  1 , Charles Dariane  2 , Eric Barret  3 , Jean-Baptiste Beauval  4   5 , Laurent Brureau  6 , Gaëlle Fiard  7 , Gaëlle Fromont  8 , Gilles Créhange  9 , Mathieu Gauthé  10 , Alain Ruffion  11   12 , Raphaële Renard-Penna  13 , Romain Mathieu  14   15 , Paul Sargos  16 , Morgan Rouprêt  17 , Guillaume Ploussard  4   5 , Guilhem Roubaud  18
Affiliations
Review

PARP inhibitors in prostate cancers, is it time for combinations?

Diego Teyssonneau et al. Ther Adv Med Oncol. .

Abstract

Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.

Keywords: DNA repair; PARP inhibitors; homologous recombination repair; metastatic prostate cancers.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Main results provided by the five phase III trials studying PARPis in metastatic prostate cancers. PROpel,, TALAPRO-2 cohort 1, TALAPRO-2 cohort 2, MAGNITUDE,, PROfound,, and TRITON-3.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. - PubMed
    1. Robinson D, Van Allen EM, Wu YM, et al.. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215–1228. - PMC - PubMed
    1. Abida W, Armenia J, Gopalan A, et al.. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol 2017; 1: PO.17.00029. - PMC - PubMed
    1. Castro E, Goh C, Olmos D, et al.. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748–1757. - PMC - PubMed
    1. Castro E, Romero-Laorden N, Del Pozo A, et al.. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2019; 37: 490–503. - PubMed

LinkOut - more resources